Evidence map›Paper›PMID 25122794›Full record

ArticleJournal of virology2014

The VP4 peptide of hepatitis A virus ruptures membranes through formation of discrete pores.

Ashutosh Shukla, Aditya K Padhi, James Gomes, Manidipa Banerjee

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 45 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. The Art of Viral Membrane Fusion and Penetration.Sub-cellular biochemistry · 2023
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Hepatitis A Virus Capsid Structure.Cold Spring Harbor perspectives in medicine · 2019
    Review
  13. Article
  14. Hepatitis A Virus Genome Organization and Replication Strategy.Cold Spring Harbor perspectives in medicine · 2018
    Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Cryo-EM study of slow bee paralysis virus at low pH reveals iflavirus genome release mechanism.Proceedings of the National Academy of Sciences of the United States of America · 2017
    Article
  20. Inhibitor-Based Therapeutics for Treatment of Viral Hepatitis.Journal of clinical and translational hepatology · 2016
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Ashutosh ShuklaKusuma School of Biological Sciences, Indian Institute of Technology-Delhi, Hauz Khas, New Delhi, India.
Aditya K PadhiKusuma School of Biological Sciences, Indian Institute of Technology-Delhi, Hauz Khas, New Delhi, India.
James GomesKusuma School of Biological Sciences, Indian Institute of Technology-Delhi, Hauz Khas, New Delhi, India.
Manidipa BanerjeeKusuma School of Biological Sciences, Indian Institute of Technology-Delhi, Hauz Khas, New Delhi, India mbanerjee@bioschool.iitd.ac.in.
Indian Institute of Technology Delhi · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

unlabelledMembrane-active peptides, components of capsid structural proteins, assist viruses in overcoming the host membrane barrier in the initial stages of infection. Several such peptides have been identified, and their roles in membrane fusion or disruption have been characterized through biophysical studies. In several members of the Picornaviridae family, the role of the VP4 structural peptide in cellular-membrane penetration is well established. However, there is not much information on the membrane-penetrating capsid components of hepatitis A virus (HAV), an unusual member of this family. The VP4 peptide of HAV differs from its analogues in other picornaviruses in being significantly shorter in length and in lacking a signal for myristoylation, thought to be a critical requisite for VP4-mediated membrane penetration. Here we report, for the first time, that the atypical VP4 in HAV contains significant membrane-penetrating activity. Using a combination of biophysical assays and molecular dynamics simulation studies, we show that VP4 integrates into membrane vesicles through its N-terminal region to finally form discrete pores of 5- to 9-nm diameter, which induces leakage in the vesicles without altering their overall size or shape. We further demonstrate that the membrane activity of VP4 is specific toward vesicles mimicking the lipid content of late endosomes at acidic pH. Taken together, our data indicate that VP4 might be essential for the penetration of host endosomal membranes and release of the viral genome during HAV entry. IMPORTANCE: Hepatitis A virus causes acute hepatitis in humans through the fecal-oral route and is particularly prevalent in underdeveloped regions with poor hygienic conditions. Although a vaccine for HAV exists, its high cost makes it unsuitable for universal application in developing countries. Studies on host-virus interaction for HAV have been hampered due to a lack of starting material, since the virus is extremely slow growing in culture. Among the unknown aspects of the HAV life cycle is its manner of host membrane penetration, which is one of the most important initial steps in viral infection. Here, we present data to suggest that a small peptide, VP4, a component of the HAV structural polyprotein, might be essential in helping the viral genome cross cell membranes during entry. It is hoped that this work might help in elucidating the manner of initial host cell interaction by HAV.

Indexed as

Virus InternalizationBiophysical PhenomenaHepatitis A virusLiposomesMembrane LipidsMolecular Dynamics SimulationViral ProteinsLiposomesMembrane LipidsViral Proteins

Identifiers

PMID25122794
PMCPMC4248947
OpenAlexW2164733984

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.